Middle East And Africa Over The Counter Drugs Market Size, Share, Opportunities, And Trends By Product (Cough, Cold, And Flu Products, Analgesics, Dermatology Products, Gastrointestinal Products, Oral Healthcare Products, Weight-loss/Dietary Products, Ophthalmic Products, Sleep Aids, Others), By Mode Of Administration (Oral, Topical, Parenteral) - Forecasts From 2022 To 2027

  • Published : Mar 2021
  • Report Code : KSI061611010
  • Pages : 114

The Middle East and Africa Over-the-Counter Drugs Market was valued at US$X.XX billion in 2020 and is projected to expand at a CAGR of XX.XX% over the forecast period to reach US$X.XX billion by 2027.  This research study examines the Over-the-Counter Drugs market on the basis of various segments. Major drivers, restraints, and opportunities have been mentioned to provide an exhaustive picture of the market. Furthermore, the current market trends related to the demand, supply, and sales, in addition to the recent developments, have been provided in this report.  The report also analyzes key players in the Over-the- Counter Drugs market. The report provides comprehensive forecast up to the period 2022 for various key segments, with 2016 as base year.        

The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical segments. Moreover, the research study analyzes the overall regulatory framework of the Middle East and Africa Over-the-Counter market, offering stakeholders a better understanding of the key factors affecting the overall market environment.

The first step towards determining the Over-the- Counter Drugs market size involves identifying key players and the revenue contribution of the overall business or relevant segment aligned to the study in consideration through extensive secondary research. This also includes various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others. Both bottom-up and top down approaches are utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the Over-the- Counter Drugs value chain, who are C-Level Executives, Directors, and Managers among others across key enterprises operating as manufacturers, suppliers, and distributors. The last phase is providing intelligence in the form of presentation, charts, graphics and other different formats helping the clients in faster and efficient understanding of the market. Under this phase complete market engineering is involved which includes analyzing the gathered data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Segments covered under the Over-the- Counter Drugs market report are as below:

By Product Category

Cough, Cold and flu products


Dermatology products

Gastrointestinal products

Vitamins, mineral and supplements (VMS)

Weight loss/Dietary products

Ophthalmic Products

Sleep Aids



By Administration





By Geography

Middle East and Africa






Key industry players profiled as part of this section are Johnson and Johnson, Novartis AG, Bayer, Sanofi, Pfizer, Inc., GlaxoSmithKine, Boehringer Ingelheim GmbH, PGT healthcare, and Takeda with few others.

The report’s target audience is as below:




Service Providers

Government Agencies

Research Organizations


1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. Key Findings of the Study
4. Market Dynamics

4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. Middle East and Africa Over-the-Counter Market Forecast by Product Category (US$ Billion)
5.1. Introduction
5.2. Cough, Cold and flu products
5.3. Analgesics
5.4. Dermatology products
5.5. Gastrointestinal products
5.6. Vitamins, mineral and supplements (VMS)
5.7. Weight loss/Dietary products
5.8. Ophthalmic Products
5.9. Sleep Aids
5.10. Others
6. Middle East and Africa Over-the-Counter Market Forecast by Administration (US$ Billion)
6.1. Introduction
6.2. Oral
6.3. Topical
6.4. Parenteral
7. Middle East and Africa Over-the-Counter Market Forecast by Geography (US$ Billion)
7.1. Introduction
7.2. Middle East and Africa
7.2.1. UAE
7.2.2. Israel
7.2.3. Qatar
7.2.4. Others
8. Competitive Intelligence
8.1. Strategies of Key Players
8.2. Recent Investments and Deals
9. Company Profiles
9.1. Covance, Inc.
9.1.1. Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Key Developments 
9.2. Johnson and Johnson
9.2.1. Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Key Developments 
9.3. Novartis AG
9.3.1. Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Key Developments 
9.4. Bayer AG
9.4.1. Overview
9.4.2. Financials
9.4.3. Products and Services
9.4.4. Key Developments 
9.5. Sanofi
9.5.1. Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Key Developments 
9.6. Pfizer, Inc.
9.6.1. Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Key Developments 
9.7. GlaxoSmithKline plc.
9.7.1. Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Key Developments 
9.8. Boehringer Ingelheim GmbH
9.8.1. Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Key Developments 
9.9. PGT healthcare
9.9.1. Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Key Developments 
9.10. Takeda Pharmaceutical Company Limited
9.10.1. Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Key Developments 
List of Tables
List of Figures

Covance, Inc.
Johnson and Johnson
Novartis AG
Bayer AG
Pfizer, Inc.
GlaxoSmithKline plc.
Boehringer Ingelheim GmbH
PGT healthcare
Takeda Pharmaceutical Company Limited